Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials

By sjmartinez • February 11, 2023

Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023 Feb 10;188(2):198-207. doi: 10.1093/bjd/ljac040. PMID: 36763857.

Tags: Dermatology, Publications

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Simpson EL, Hebert AA, Browning J, Serrao RT, Sofen H, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM. Tapinarof Improved Outcomes and Sleep for Patients[...]

Gender differences in pain interference with daily activities and functional impairment among patients with hidradenitis suppurativa: A population-based study in the United States

Kingston P, Peterson H, Lee K, Huang MY, Yee D, Korouri E, Armstrong AW. Gender differences in pain interference with daily activities and functional impairment[...]

Artificial Intelligence and Dermatology

Wongvibulsin S, Lee I. Artificial Intelligence and Dermatology. JAMA Dermatol. 2025 Jan 8. doi: 10.1001/jamadermatol.2024.4645. Epub ahead of print. PMID: 39774621.